Drug Profile
Telotristat etiprate - TerSera Therapeutics
Alternative Names: LP-778914; LX-1032; LX-1606; LX1032 hippurate; LX1606 hippurate; Telotristat ethyl; XermeloLatest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Lexicon Pharmaceuticals
- Developer Ipsen; Lexicon Pharmaceuticals
- Class Amines; Anti-inflammatories; Antineoplastics; Chlorobenzenes; Fluorinated hydrocarbons; Propionic acids; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Tryptophan hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Malignant carcinoid syndrome
- Phase II Neuroendocrine tumours
- Preclinical Cholangiocarcinoma; Colorectal cancer; Liposarcoma
- Discontinued Biliary cancer; Ulcerative colitis
Most Recent Events
- 18 Jan 2024 Efficacy and adverse events data from a phase II trial in Biliary tract cancer presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 21 Feb 2023 TerSera Therapeutics and University of Kentucky terminates a phase-II clinical trials in Neuroendocrine tumours (In adults, In the elderly, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Combination therapy) in USA (PO, Tablet) as sponsor cancelled research (NCT04543955)
- 05 May 2022 Novartis suspends a phase II trial in Neuroendocrine tumours (In adults, In the elderly, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Combination therapy) in USA (PO) due to production suspension of Lutathera (NCT04543955)